Purchase Order 75N95024P00459
- Not listed
- This federal contract award is for $313,500.00 in single cell multiome sequencing services, provided by Psomagen Inc., a subsidiary of Macrogen, Inc. The contract was awarded by the National Institute on Aging (NIA), a civilian agency within the National Institutes of Health (NIH). The contract is a firm fixed price purchase order with a period of performance through March 1, 2026. Psomagen Inc. is a prime contractor that specializes in delivering a wide range of genomic and molecular biology...
- This is a $3,849,800.00 firm fixed-price purchase order contract awarded to Psomagen Inc., a small business, by the National Institute on Aging (NIA), a component of the National Institutes of Health (NIH). The contract is for neurodegenerative disease research, including whole genome sequencing services, with a completion date of September 14, 2024. Psomagen Inc. is a subsidiary of Macrogen, Inc. and is a provider of genomic sequencing, bioinformatics, and related services to federal government...
- This firm-fixed price purchase order for $600,000 was awarded by the National Institute on Aging, a component of the National Institutes of Health within the Department of Health and Human Services, to Psomagen, Inc. for whole genome sequencing services. Under the terms of the contract, Psomagen will sequence 1,000 human samples to 30x coverage using Illumina sequencing technologies and deliver raw sequencing data files within 4-6 weeks. The work will be performed in Potomac, Maryland over a one...
- This federal contract award to Psomagen Inc., a subsidiary of Macrogen, Inc., is for epigenome sequencing services using the Illumina NovaSeq platform. The $83,750 firm fixed-price purchase order was awarded by the National Institute on Aging, a civilian agency within the National Institutes of Health. The award was not set aside for small businesses. Psomagen Inc. is an experienced provider of genomic services to federal agencies, having supported research initiatives at the NIH, USDA, and...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Psomagen Inc., a subsidiary of Macrogen, Inc. The $10,000.00 firm fixed-price purchase order is for DNA sequencing services. The contract has no set-aside designation. Psomagen Inc. is a provider of genomic and molecular biology services, including whole genome sequencing, RNA sequencing, and epigenome sequencing, that supports...
- The National Institute on Aging (NIA), a civilian agency within the Department of Health and Human Services, awarded a $532,500 firm-fixed-price purchase order contract to Psomagen Inc., a small business contractor, for long read sequencing services. This contract supports the Global Parkinson's Genetics Program (GP2) research initiative and requires Psomagen to perform whole genome sequencing of 500 human DNA samples at 25X coverage. Psomagen is a multiomics contract laboratory that specializes...
- This federal contract award, with a ceiling value of $27,600, was issued by the National Institute of Mental Health (NIMHD) to Psomagen Inc., a subsidiary of Macrogen, Inc. The contract is for bioinformatics services related to RNA/DNA sequencing. Psomagen, a small business, has a history of providing genomic services to various federal agencies, including the National Institutes of Health (NIH), U.S. Department of Agriculture (USDA), and Smithsonian Institution, through both contract and...
- This is a federal purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), to Psomagen Inc., a subsidiary of Macrogen, Inc. The contract, valued at $4,942.00, is for DNA sequencing services. It is not a set-aside contract. The contract supports NIAID's research efforts, potentially including work on neurodegenerative diseases, cancer, and infectious diseases. Psomagen has previously received...
- The National Institute on Aging (NIA), a civilian agency within the U.S. government, has awarded a $237,440.00 firm fixed-price purchase order to Psomagen Inc., a for-profit organization and manufacturer of goods, to provide next-generation sequencing analysis services on post-mortem frontal cortex tissues. The contract has an ultimate completion date of July 31, 2025. This award is not associated with a set-aside program. Psomagen Inc. is a subsidiary of Macrogen, Inc. and is a multiomics...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Psomagen Inc., a subsidiary of Macrogen, Inc. The $30,000 firm fixed-price purchase order was not set aside for any specific business type. Under this contract, Psomagen will provide a range of genomic and molecular biology services to support research across various NIH institutes, including the National Institute on Aging,...
This federal contract, awarded by the National Institute on Aging (a civilian agency of the U.S. government), is for the purchase of whole genome sequencing services from the prime contractor, Psomagen Inc. The contract has a total ceiling value of $7,499,725.00 and is set aside for small businesses. Psomagen Inc. is a subsidiary of Macrogen, Inc. that specializes in providing a range of genomic sequencing, bioinformatics, and related services to federal agencies. Through this contract, Psomagen will likely support the National Institute on Aging's research initiatives, which may include studies on neurodegenerative diseases and other areas of interest to the institute. Psomagen also holds several other significant federal contracts, including an Indefinite Delivery Vehicle (IDV) with the USDA for Sanger sequencing services and a $500 million IDV with the NIH National Heart, Lung and Blood Institute to support the Trans-Omics for Precision Medicine (TOPMed) initiative.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00001 | Exercise an Option | $1.8m | 9/24/24 | |
| Not listed | Not listed | $115.5k | 8/19/24 |